1h Free Analyst Time
The non-cancerous skin diseases therapeutics market is forecasted to grow by USD 31.46 billion during 2024-2029, accelerating at a CAGR of 11.1% during the forecast period. The report on the non-cancerous skin diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of skin diseases, strong pipeline landscape in non-cancerous skin diseases therapeutics, and growing demand for personalized non-cancerous skin diseases therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The non-cancerous skin diseases therapeutics market is segmented as below:
By Therapy Area
- Psoriasis
- Eczema
- Acne vulgaris
- Others
By Route Of Administration
- Injectable
- Oral
- Topical
By End-user
- Hospitals
- Dermatology Clinics
- Homecare
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the non-cancerous skin diseases therapeutics market covers the following areas:
- Non-Cancerous Skin Diseases Therapeutics Market sizing
- Non-Cancerous Skin Diseases Therapeutics Market forecast
- Non-Cancerous Skin Diseases Therapeutics Market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Therapy Area
9 Market Segmentation by Route of Administration
10 Market Segmentation by End-user
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity/Restraints
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global non-cancerous skin diseases therapeutics market: AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Incyte Corp., LEO Pharma AS, Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., UCB SA, Viatris Inc., and XBiotech Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increased focus on microbiome and skin barrier."
According to the report, one of the major drivers for this market is the high prevalence of skin diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- Bristol Myers Squibb Co.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Galderma SA
- GlaxoSmithKline Plc
- Incyte Corp.
- LEO Pharma AS
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Sanofi SA
- Sun Pharmaceutical Industries Ltd.
- UCB SA
- Viatris Inc.
- XBiotech Inc.
